Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-06-23
2010-11-23
Marvich, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C514S04400A, C435S069100, C435S069200, C435S091400, C435S320100
Reexamination Certificate
active
07838294
ABSTRACT:
JNK-interacting protein 1 (JIP-1), an inhibitor of the JNK1 protein, and methods of treating a pathological condition or of preventing the occurrence of a pathological condition in a patient by the administration of a therapeutically effective amount of JIP-1 polypeptides, peptides, peptide mimetics, or nucleic acids are described.
REFERENCES:
patent: 6610820 (2003-08-01), Bonny
patent: 9706731.8 (1997-05-01), None
patent: WO 98/44106 (1998-10-01), None
Guo et al, Protein tolerance to random amino acid change, PNAS, 2004, vol. 101 (25), pp. 9205-9210.
Lesk et al, Prediction of Protein Function from Protein Sequence and Structure, p. 27 and 28, downloaded Sep. 16, 2007.
Opalinska and Gewirtz, Nucleic-Acid Therapeutics: Basic Principles and Recent Applications, Nature Reviews, 2002, vol. 1, pp. 503-514.
Russell, S. J., Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects, European J Cancer, 1994, vol. 30A (8), pp. 1165-1171.
Adams et al., GenBank Accession No. U62317, (submitted Jun. 26, 1996).
Andersson et al., GenBank Accession No. U79261, (submitted Nov. 22, 1996).
Choi et al., “Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating Cerevisiae”, Cell 78:499-512, 1994.
Davis, “MAPKs: new JNK expands the group”, TIBS 19:470-473, 1994.
Dérijard et al., “JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain”, Cell 76:1025-1037, 1994.
Dérijard et al., “Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and Isoforms”, Science 267:682-685, 1995.
Dickens et al. Database Accession No. AF003115, (submitted May 7, 1997).
Dickens et al. “A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway” Science 277:693-696, 1997.
DiMari et al., “N-acetyl Cysteine Ameliorates Ischemic Renal Failure”, Am. Physiological Soc. 272:F293-F298, 1997.
Enrico, Journal of Alzheimer's disease, JAD 1:67-78, 2004, abstract.
Faux et al., “Molecular Glue: Kinase Anchoring and Scaffold Proteins”, Cell 85:9-12, 1996.
Force et al., “Stress-Activated Protein Kinases in Cardiovascular Disease”, American Heart Association 78:947-953, 1996.
Galcheva-Gargova et al., “An Osmosensing Signal Transduction Pathway in Mammalian Cells”, Science 265:806-808, 1994.
Glozman et al. “Evidence that signal transduction by oncogenicras-p21 protein depends on its interaction withjunkinase andjunproteins” Med. Sci. Res. 24:331-333, 1996.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty”, Science 278:1041-1042, 1997.
Hibi et al., “Identification of an oncoprotein-and UV-responsive protein kinase that binds and the c-Jun activation domain”, Genes & Dev. 7:2135-2148, 1993.
Kabouridis, P. “Biological applications of protein transduction technology”, TIBS 21 (11):498-503, 2003.
Lin et al., “Identification of a Dual Specificity Kinase That Activates the Jun Kinases and p38-Mpk2” Science, 268:286-290, 1995.
Loregian et al., “Use of Vibrio spp. for expression ofEscherichia colienterotoxin B subunit fusion proteins” Protein Expression and Purification 8:381-389, 1996.
Mendelson et al., “Independent Regulation of JNK/p38 Mitogen-Activated Protein Kinases by Metabolic Oxidative Stress in the Liver”, Proc. Nat'l. Acad. Sciences USA 93:12908-12913, 1996.
McNeil et al., “Interaction of Autophosphorylated Ca2+/Calmodulin-dependent Protein Kinase II with Neuronal Cytoskeletal Proteins”, J. of Biol. Chemistry 270:10043-10049, 1995.
Minden et al., “Differential Activation of ERK and JNK Mitogen-Activated Protein Kinases by Raf-1 and MEKK” Science 266:1719-1723, 1994.
Mooser et al. “Genomic Organization, Fine-Mapping, and Expression of the HumanIslet-Brain 1(IB1)/C-Jun-Amino-Terminal Kinase Interacting Protein-1(JIP-1) Gene” Genomics 55:202-208, 1999.
Pombo et al., “The Stress-Activated Protein Kinases Are Major c-Jun Amino-Terminal Kinases Activated Ischemia and Reperfusion”, J. of Biol. Chemistry 269:26546-26551, 1994.
Riesgo-Escovar et al., “The Drosophila Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye” Genes & Dev. 10:2759, 1996.
Scheinfeld, “Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1” Journal of Biological Chemistry, vol. 278 (43):42058-42063, 2003, abstract.
Sluss et al., “Signal Transduction by Tumor Necrosis Factor Mediated by JNK Protein Kinases”, Mol. Cell Biol. 14:8376-8384, 1994.
Sluss et al., “A JNK signal transduction pathway that mediates morphogenesis and an immune response in Drosophila ” Genes & Dev., 10:2745, 1996.
Torchilin and Lukyanov, “Peptide and protein drug delivery to an into tumors: challenges and solutions,” DDT 8(6):259-266, 2003.
Wang et al., “Intestinal absorption studies on peptide mimetic α-methyldopa prodrugs” J. of Pharmacy Pharmacology 48(3):270-276, 1996.
Wei Wang, “Instability, stabilization, and formulation of liquid protein pharmaceuticals” International Journal of Pharmaceutics 185:129-188, 1999.
Whitmarsh et al., “Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways” J. Mol. Med. 74:589-607, 1996.
Xia et al., “Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis”, Science 270:1326-1331, 1995.
Zhou et al., “Liposome-mediated cytoplamic delivery of proteins . . . ” Immunomethods 4(3):229-235, Database Medline on STN, 1994 Abstract.
Borsello et al, “A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia”, Nature Medicine, vol. 9 No. 9, pp. 1180-1186 (2003).
Haefliger et al, “The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic β cells”, Journal of Cell Science, vol. 116, pp. 1463-1469 (2003).
Hirt et al, “D-JNKI1, a Cell-Penetrating c-Jun-N-Terminal Kinase Inhibitor, Protects Against Cell Death in Severe Cerebral Ischemia”, Stroke, vol. 35, pp. 1738-1743 (2004). © 2004 American Heart Association, Inc.
Kaneto et al, “Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide”, Nature Medicine, vol. 10 No. 10, pp. 1128-1132 (2004).
J.T. Ngo, J. Marks and M. Karplus.Computational complexity, protein structure prediction, and the Levinthal paradox, In:The protein folding problem and tertiary structure prediction, K.M. Merz and S.M. Le Grand eds., Birkhauser, Boston, (1994).
Schwarze et al, “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse”, Science, vol. 285. Issue 5433, pp. 1569-1572 (1999), obtained from www.sciencemag.org/cgi/content/full/285/5433/1569.
Davis Roger J.
Dickens Martin
Fish & Richardson P.C.
Marvich Maria
University of Massachusetts
LandOfFree
Inhibitors of the JNK signal transduction pathway and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the JNK signal transduction pathway and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the JNK signal transduction pathway and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242640